ntec Pharma Ltd. (Nasdaq: NTEC), a late stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, announces that Company management will participate at the 29 th  Annual Roth Conference taking place from March 13-15, 2017 at the Ritz

JERUSALEM, March 10, 2017 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ; TASE: NTEC), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, today announced that it has entered into agreements with several investors for the

JERUSALEM, November 28, 2016 /PRNewswire/ -- Intec Pharma Ltd. (Nasdaq: NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, announces it has entered into an agreement with the Michael J.

JERUSALEM, November 9, 2016 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, announces that the Company will be hosting an investigator meeting

Sample size reduced from 460 to 328 patients without altering the trial's objectives, endpoints or statistical powering JERUSALEM, November 7, 2016 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP), a clinical-stage biopharmaceutical company focused on developing drugs based on its

Strengthens protection for Intec Pharma's leading Parkinson's disease product currently in a global Phase III clinical trial Intec Pharma Ltd. (NASDAQ:NTEC) (TASE:INTP), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform

Intec Pharma Ltd. (Nasdaq:NTEC), a late stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, announces that Company management will participate at the Rodman & Renshaw 18th Annual Global Investment Conference taking place from

Fortifies protection for Intec Pharma's leading product for Parkinson's disease currently in a global Phase III clinical trial Intec Pharma Ltd. (Nasdaq: NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology,

Intec Pharma Ltd. (Nasdaq: NTEC), a late stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, reports financial results for the three and six months ended June 30, 2016. Highlights of the first six months of 2016 and recent weeks

Phase 1 clinical trial to begin in first quarter 2017 Intec Pharma Ltd. (Nasdaq:NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, announces the initiation of a new clinical development program for its